11.01.03
Indication: Lung and prostate cancers
Source: Cancer Epidemiology Biomarkers & Prevention, 2003;2003:518-526.
Research: Researchers analyzed data from the Beta-Carotene and Retinol Efficacy Trial (CARET). They focused on blood samples from 278 subjects with lung cancer, 205 subjects with prostate cancer and 483 matched subjects without cancer. They analyzed blood levels of several carotenoids, including vitamin A and vitamin E (alpha and gamma tocopherols), then identified correlations between those levels and the risk of lung and prostate cancer.
Results: In the overall population, the highest intakes of lutein, zeaxanthin and alpha-tocopherol were associated with a significantly lower risk of lung cancer. Women with the highest blood levels of lutein, zeaxanthin and beta-cryptoxanthin had the lowest risk of developing lung cancer. The risk reduction associated with these nutrients was 69% for lutein and zeaxanthin and 66% for beta-cryptoxanthin. Men with the highest blood levels of alpha-tocopheral were 41% less likely to develop prostate cancer.
Source: Cancer Epidemiology Biomarkers & Prevention, 2003;2003:518-526.
Research: Researchers analyzed data from the Beta-Carotene and Retinol Efficacy Trial (CARET). They focused on blood samples from 278 subjects with lung cancer, 205 subjects with prostate cancer and 483 matched subjects without cancer. They analyzed blood levels of several carotenoids, including vitamin A and vitamin E (alpha and gamma tocopherols), then identified correlations between those levels and the risk of lung and prostate cancer.
Results: In the overall population, the highest intakes of lutein, zeaxanthin and alpha-tocopherol were associated with a significantly lower risk of lung cancer. Women with the highest blood levels of lutein, zeaxanthin and beta-cryptoxanthin had the lowest risk of developing lung cancer. The risk reduction associated with these nutrients was 69% for lutein and zeaxanthin and 66% for beta-cryptoxanthin. Men with the highest blood levels of alpha-tocopheral were 41% less likely to develop prostate cancer.